ASCO Drink Machines offers beverage dispensers, including the FRUCTOMAT system, designed for a variety of drinks including fruit juices and soft drinks.

ASCO Drink Machines

Austria Juice is a manufacturer of beverage compounds and flavors, offering products for various markets in the food and beverage sector.

Austria Juice

American Society of Clinical Oncology (ASCO) | 124,981 followers on LinkedIn. Conquering cancer through research, education, and promotion of the highest quality, equitable patient care. | Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality and equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

Residency- Fellowship at National Cancer Institue- Clinical Center

Richard McGee

Melinda O'Leary

Chief Digital Officer (CDO) at American Society of Clinical Oncology (ASCO)

Christopher Merlan

Lizhe Sun

American Society of Clinical Oncology (ASCO)

Conversations sparked. Connections made. More than 45,000 attendees came together at #ASCO24 to explore the art & science of oncology and left inspired to change the future of cancer care. Thanks to all who joined us! Save the date for #ASCO25 : May 30–June 3, 2025

Voting in the ASCO Election is open now until December 3! Meet the candidate for President-Elect, Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO. This seat has a four-year term, and there is one seat available. Learn more about Dr. Mittendorf and make your voice heard at https://brnw.ch/21wOn8p

We are excited to launch our Latin America International Clinical Research Scholars program in São Paulo, Brazil, hosted by Sírio-Libanês Hospital. Our ICR Scholars are discussing their research ideas with experts and learning about research ethics, study design, biostatistics, avoiding research bias, common sense oncology, and more. The ICRS is a 1-year hybrid program for investigators that pairs research education with mentorship. Thank you to our course faculty, host, and Scholars! https://brnw.ch/21wOjtR

The ACHO Defying Cancer Award competition is officially OPEN! If you’re a hematology or oncology researcher in Colombia, now is your chance to apply for funding. Start your LOI today! https://brnw.ch/21wOiQW #CancerResearch #GrantOpportunity #EveryGrant American Society of Clinical Oncology (ASCO)

Conquer Cancer, the ASCO Foundation

Vote now in the ASCO Election! Today through December 3 at 3 PM (ET), we encourage all eligible members to cast their ballots to help choose the Society’s future leaders. Learn more about each candidate and then make your voice heard at: https://brnw.ch/21wOiOB 🗳️

In a The Wall Street Journal letter-to-the-editor, our CEO Clifford Hudis describes how we're supporting all clinicians - particularly those in remote areas. "We recently launched a program that brings top-notch cancer care and knowledge from a “hub” facility in Bozeman, Mont., to the rural “spoke” community of Dillon, ensuring patients get the care they need without having to travel for hours. This is a model we hope can be replicated." More in the WSJ ➡️ https://brnw.ch/21wOh20 To learn more about our program in Montana ➡️ https://brnw.ch/21wOh1Z

One of my friends and colleagues asked me to discuss EB1 processing so I decided I'd create a post about it so everyone can benefit from my experience. In addition to helping the #InternationalMedicalGraduates #IMGs who walk long ways to get to Green card, I believe this might help mitigate issues around #RuralHealthCare and #WorkforceShortages #PhysicianBurnOut #PhysicianWellBeing as well.. For those who dont know, EB1 is the extraordinary ability category created by the United States Citizenship and Immigration Services (USCIS); while the regular H1B visa goes through EB2 processing that can take several years for immigrants from certain countries, EB1 processing garners shorter processing times. I am an Indian immigrant, who trained on J1 Visa and did a waiver; the wait period for Indians for permanent residency can be >10 years; The Sept 2024 processing times on the USCIS website show that for Indian applicants, those who filed in July 2012 are going through processing currently, 12+ years of wait time. Needless to say the families of such candidates may stay on the same visa status and it impacts their chances of getting into colleges/ schools as well, which is so unfair. I am sharing my personal experience and some relevant points that helped me file and successfully get to a faster EB1 processing and hence permanent residency.. (Not all might be applicable to your situation and this is not a legal advice, just my own experience)..Good luck.. #RuralOncology American Society of Clinical Oncology (ASCO)

Jasmine Kamboj, MD, FASCO

AI has been making waves everywhere, including in the medical field. That's why the American Society of Clinical Oncology (ASCO) recently put together a list of six principles for using AI in oncology care. These principles are designed to help balance the risks and rewards when it comes to AI. Debra Patt, MD PhD MBA , Chair of ASCO's AI Task Force, says that “we want patients to benefit from this tremendous innovation, and it’s a very exciting time." However, she continues, "we have to be cognizant and responsible about the fact that these tools might have bias and errors. We need responsible guiding principles to see us through how we optimally benefit from these important technologic advances.” Read the full Healio interview here: https://lnkd.in/gtRv_uTP #OncologyCare #MedicalAI #HealthcareTech

The US Oncology Network

I was reminded the other day of an essay I wrote for the American Society of Clinical Oncology (ASCO) 's site, ASCO Connection. The most important and meaningful gifts I've received from patients over the years have not been those that can be wrapped in festive paper. From the essay: "The most important gift my patients have given me, however, has been the opportunity to be a part of their lives, to be let into their world and to share a part of their cancer experience with them." https://lnkd.in/etRvi5qt

Metric
Company Name	ASCO Drink Machines	Austria Juice
Symbol
MSH ID	AT:ASCO	COM:AUSTRIAJUICE
Market	PRIVATE	PRIVATE
Sector	Consumer Goods	Consumer Goods
Industry	Beverage Equipment Manufacturing	Food & Beverage
Country	AT	AT
Stage
Employee Count	11
Website	asco.at	austriajuice.com
LinkedIn	american-society-of-clinical-oncology	austria-juice-gmbh
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.12K	3.95K
Web Traffic Growth		-0.16
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ASCO

AT:ASCO

ASCO Drink Machines

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue